Try for free
Base to Base Biotech
Base to Base Biotech

Base to Base biotech podcast 49: Gene therapy for kidney disease, and using AI to transform diagnostics

06 March 2026 51:32 Jim Cornall

Listen to episode

About this episode

This week, we’re chatting with Haseeb Ahmad, CEO of Purespring Therapeutics, about gene therapies in kidney disease, and with Pahini Pandya, Panakeia CEO, about colorectal cancer biomarkers, the potential of AI in clinical decision-making and how AI can transform workflows in diagnostics.

Times:

03:34 Purespring

24:11 Panakeia Technologies

Purespring Therapeutics

Purespring is a precision nephrology company pioneering first-in-class, targeted genetic therapies designed to preserve kidney function.

The company is focused on transforming the treatment of kidney disease—an area of enormous unmet need, with more than 840m people worldwide living with chronic kidney disease.

Purespring’s lead programme, PS-002, for IgA nephropathy (IgAN) is set to enter the clinic this quarter. It marks the first podocyte-targeted gene therapy to reach clinical development and offers a highly differentiated approach compared with other emerging treatments, including those from Vertex and Otsuka.

Panakeia Technologies

Panakeia Technologies recently published a real-world clinical validation showing that AI can determine critical colorectal cancer biomarkers in minutes, in a test across 1,243 patients and 3,576 images in NHS hospitals.

While not yet used directly in patient care, the study demonstrates the potential for AI to support clinical decision-making, reduce lab bottlenecks, and help clinicians act faster — a topic highly relevant to the goals of the UK government's cancer plan and the ongoing discussion around innovation in healthcare.

To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email [email protected]

More AI podcast episodes

Browse all →

Want to find AI jobs?

Join thousands of AI professionals finding their next opportunity

We respect your inbox. Unsubscribe at any time.

© 2026 Base to Base Biotech. All rights reserved.

Common Questions

Frequently asked questions

Quick answers about how DevFound's AI matching, resumes, and referrals work.

DevFound's AI Copilot ingests your profile, goals, and live job data to deliver curated matches in seconds. Every match includes a resume variant, suggested referrals, and interview prep so you can act immediately. The more feedback you provide, the sharper the Copilot becomes.

AI-led job searches shrink the hours spent sifting through boards and formatting resumes. DevFound pairs automation with your personal outreach, so you reserve energy for interviews and negotiation. Traditional networking still matters, but AI gives you a lift before you even send a message.

Modern AI roles expect comfort with production-grade code, data fluency, and practical ML tooling. The strongest candidates pair deep technical chops with storytelling—translating model impact to product, GTM, and exec partners. Continuous learning keeps you ahead as stacks evolve.

DevFound rewards active seekers. Keep your profile fresh, respond to match quality prompts, and enable alerts so you never miss a role. The AI prioritizes companies and teams that align with your feedback, accelerating both introductions and interview invites.

High-density tech hubs continue to host the deepest AI talent pools, yet distributed teams are catching up fast. Use DevFound filters to hone in on onsite, hybrid, or fully remote roles and watch openings expand across time zones.

DevFound aggregates thousands of remote AI openings and flags the nuances—core hours, async culture, and visa needs—up front. The Copilot also recommends how to position your distributed work experience so hiring managers know you can thrive on a remote team.

Still have questions?

Contact Support